Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > THAT WAS THE REACTION

<< Previous

Bullboard Posts

Next >>

Comment by WORKINMONTANAon Apr 01, 2021 10:37am

106 Views

Post# 32922412

RE:RE:RE:RE:RE:THAT WAS THE REACTION

The share count of $DML is 809 million and it's going higher. You are a tool Edward Vranic

losingmyshirt wrote: I was invested in kaly for a few years.. Happy to be out but I want to make sure that newbies coming in don't fall for the pump and hype.
Kaly's past is worth checking out.
From highs in the .30's all the way down down to .02
They have accomplished nothing so far.